What's breaking now, across thousands of outlets.
Moderna’s upsized note offering quickly followed a big win in a crucial study. Elsewhere, a biotech’s shares tumbled after study data were “inadvertently” published ahead of a medical meeting.
We haven't written up this one. BioPharma Dive has the full story — the link below goes straight to it.
FDA cancels Cipla unit's drug licence: During an inspection in June, FDA officials found that the packaging of Reactin Plus Tablets, a Schedule H prescription medicine, carried an unauthorised claim…
Key PointsVanEck Biotech ETF offers a more affordable expense ratio of 0.35% compared to 0.57% for Invesco Pharmaceuticals ETF.
Nigeria has recorded a new milestone in advanced cancer treatment with the deployment of Actinium-based radiopharmaceutical therapy at Loveworld Medical read more Nigeria records new cancer treatment…
New research by Malaghan's Connor Laboratory, published in PNAS, shows how directing the immune system toward conserved areas of the COVID virus and its many variants using RNA technology could be a…
Despite narratives of a growing political divide between the sexes, new research shows that men and women actually shift their opinions in parallel.
PEOPLE do not realize that Alzheimer’s disease is not necessarily old age forgetfulness. It is a progressive and fatal affliction, and a staggering number of people develop this dementia every day.
